The Jak2 kinase activity is also required for tumor progression, as treatment of Pax5Jak2/+ tumor‐bearing mice with the JAK1/2 inhibitor ruxolitinib delayed tumor growth leading to prolonged survival. This evidence concerns the gene JAK1 and neoplasm.